Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling
Executive Summary
In a watershed decision, a federal appeals court declares that manufacturers cannot be prosecuted under the FD&C Act’s misbranding provisions solely for speech promoting off-label use of a drug. Industry attorneys predict the decision, if it stands, will change the government’s approach to pursuing such cases.
You may also be interested in...
Off-Label Use Discussions Should Stay Off-line, FDA Draft Guidance Says
FDA advises companies to respond to unsolicited requests for off-label information in one-on-one dialogue; the agency also requests public comments on its policies regarding off-label communications in response to an industry citizen petition.
Sales Rep's Free Speech Challenge Of Off-Label Regs Boosted By Sorrell Ruling
The Supreme Court's ruling that Vermont's prescriber data mining law violates the First Amendment could help a pharma sales representative to overturn his conviction for promoting a drug for off-label uses.
FDA Pressed To Clarify Permissible Formulary, Clinical Guideline Communications
Citizen petition from seven firms asks agency to issue regulations related to four areas of off-label communications.